MET Facts
Psychedelic;
Description
MET (N-methyl-N-ethyltryptamine) is a synthetic psychedelic of the tryptamine class. It activates serotonin receptors in the brain, disrupting normal sensory filtering and producing the perceptual and cognitive shifts characteristic of classical psychedelics.[1]
Subjective effects include geometric visual patterns, color enhancement, euphoria, time alteration, and a buzzing physical energy throughout the experience. The overall character is stimulating and grounded — more energized than DMT and without DMT's immersive perceptual overwhelm, with a persistent physical buzz defining the dose range.
MET does not produce physical dependence, and no lethal dose has been established in any species.[2] The primary risks are psychological — panic, paranoia, and psychotic reactions — amplified by the compound's stimulating character; combining it with monoamine oxidase inhibitors or lithium creates risk of life-threatening serotonin overload or seizures.[3]
Dose and durationby route · individual sensitivity varies
Starts in 1 – 2 hoursLasts 4 – 6 hoursAfter-effects 6 – 24 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 14 days
- Carries over to
- DMT;
psilocybin; LSD; mescaline; serotonergic psychedelics
Effectslikely at a common dose
- Perception
- Color enhancement;
Visual drifting; Color alteration; Geometry; +30 possible, including Visual haze / noise, Spatial disorientation, Vestibular distortion - Body
- Pupil dilation;
Body high; +27 possible, including Dizziness, Heart rate perception changes, Motor control impairment - Thinking
- none likely · 32 possible, including Confusion, Cognitive impairment, Memory suppression
- Feeling
- none likely · 8 possible, including Emotional lability, Anxiety, Paranoia
- Self
- none likely · 9 possible, including Derealization, Depersonalization, Communication suppression
- Time
- Time alteration;
+3 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 3 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Glennon RA, Teitler M, Sanders-Bush E (1992) Hallucinogens and serotonergic mechanisms — NIDA Research Monograph PMID:1435968
- [2]^Tittarelli R, Mannocchi G, Pantano F, Romolo FS (2015) Recreational use, analysis and toxicity of tryptamines. — Current neuropharmacology doi:10.2174/1570159x13666141210222409
- [3]^Malcolm B, Thomas K (2022) Serotonin toxicity of serotonergic psychedelics — Psychopharmacology doi:10.1007/s00213-021-05876-x